Arvinas Presented Phase 1 Parkinson's Data

The company reported dose-dependent improvements in oculomotor function and biomarkers for its drug ARV-102.

Updated on Oct. 7, 2026 in Alzheimer’s

A microscopic view of glowing protein structures in a lattice, representing medical research into neurological biomarkers. — Arvinas reported positive Phase 1 clinical results for its oral drug ARV-102, which showed neurological improvements in patients with Parkinson's disease. AI Illustration. Upload story photo >

Live Poll

Do you believe current medical research is making sufficient progress in treating diseases like Parkinson's?

Arvinas shared final Phase 1 clinical trial results for its investigational drug ARV-102 at the International Congress of Parkinson's Disease and Movement Disorders. The oral PROTAC degrader showed positive impacts on neurological markers in patients after 28 days of treatment.

Why it matters

Researchers are testing ARV-102 to determine if it can successfully cross the blood-brain barrier to treat neurodegenerative diseases. The study results provide early evidence of the drug's biological impact on Parkinson's disease through the modulation of LRRK2 proteins.

The trial evaluated oral doses of ARV-102 ranging from 20 mg to 80 mg administered over 28 days to 24 study participants. Results indicated dose-dependent increases in the amplitude of saccadic hypometria and reductions in CSF LRRK2 protein levels.

The players

Arvinas

Headquartered in New Haven, Connecticut, this clinical-stage biopharmaceutical company focuses on developing protein degradation therapies.

The details

The study utilized ARV-102, an oral PROTAC degrader designed to cross the blood-brain barrier to influence neuroinflammation and synaptic integrity. Patients who received the treatment showed improvements in oculomotor function that correlated directly with observed reductions in specific protein biomarkers.

Arvinas presented the Phase 1 trial data on October 7, 2026.

The Big Picture

This research contributes to the broader development of PROTAC degrader therapies for neurodegenerative conditions. The study updates the current scientific understanding of how targeted protein degradation can influence neurological markers in human patients.

The study findings suggest potential future treatment avenues for those living with Parkinson's disease, though the drug remains in early-stage development. Patients should continue to follow current standard-of-care protocols as further clinical evaluations are conducted.

The takeaway

The successful modulation of LRRK2 biomarkers in this small cohort provides a promising signal for the potential of orally administered protein degraders. Future trials will be essential to determine if these early physiological changes translate into meaningful long-term clinical benefits.